Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05935969 |
Other study ID # |
2305-030-1429 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 1, 2022 |
Est. completion date |
May 1, 2023 |
Study information
Verified date |
July 2023 |
Source |
Seoul National University Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Cholecystectomy is recommended for patients with both gallbladder (GB) and common bile duct
(CBD) stones to prevent recurrent biliary complications, unless there are specific reasons
for surgery is considered inappropriate. The aim of this study was to evaluate the role of
transpapillary gallbladder stent placement in surgically unfit patients with both CBD stone
and gallstone.
Description:
Gallstones affect 10-15% of the adult population, and 10-25% of them may develop biliary pain
or complications. Patients with symptomatic gallstones often have a concomitant CBD stone in
10-20% of them. Most gallstones do not require invasive treatment due to their benign natural
history, but CBD stones should be removed due to the risk of developing gallstone-related
complications such as obstructive cholangitis and acute gallstone pancreatitis. CBD stones
result mainly from the migration of gallstones into the bile duct, so the gold standard
treatment for gallstones with CBD stones is endoscopic removal of the CBD stone followed by
cholecystectomy to prevent recurrent biliary complications, such as calculous cholangitis or
acute cholecystitis.
However, patients who were ineligible for surgery due to high-risk conditions, including the
elderly, critically ill status, and severe underlying morbidities, may not get the chance to
undergo cholecystectomy. Initial nonoperative management with delayed cholecystectomy has
been considered as an alternative treatment, but laparoscopic cholecystectomy reduces the
rate of major complications compared with percutaneous gallbladder drainage, even in
high-risk patients, and outcomes after early laparoscopic cholecystectomy in octogenarians
are comparable to younger patients. Despite this evidence, there are still debates among
experts for optimal treatment methods for high-risk patients for surgery with symptomatic CBD
stone with gallstone, and gallbladder drainage therapy first to perform for stabilization
with surgery rather than urgent cholecystectomy in real practice. Therefore, there is still
an unmet need for how to prevent recurrence of CBD stones in patients with concomitant
gallstones after endoscopic removal of CBD stones.
Nonsurgical cholecystic drainage methods, including percutaneous transhepatic gallbladder
drainage (PTGBD), endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), and endoscopic
transpapillary gallbladder drainage (ETGBD), have been introduced and actively used as a
bridge or alternative therapy in patients at high risk for surgery. Several studies have
reported the results of its feasibility and efficacy, mainly focusing on the management of
patients with acute cholecystitis. However, the evidence for appropriate management
considering non-surgical treatments for patients with both CBD stones and gallstones is still
limited. This study evaluated the feasibility and efficacy of ETGBD for patients with both
CBD stone and gallstones to prevent recurrent biliary complications in patients at high risk
for surgery.